AU2001262257B2 - Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists - Google Patents

Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists Download PDF

Info

Publication number
AU2001262257B2
AU2001262257B2 AU2001262257A AU2001262257A AU2001262257B2 AU 2001262257 B2 AU2001262257 B2 AU 2001262257B2 AU 2001262257 A AU2001262257 A AU 2001262257A AU 2001262257 A AU2001262257 A AU 2001262257A AU 2001262257 B2 AU2001262257 B2 AU 2001262257B2
Authority
AU
Australia
Prior art keywords
compound
formula
free base
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001262257A
Other languages
English (en)
Other versions
AU2001262257A1 (en
Inventor
Joachim Nozulak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001262257A1 publication Critical patent/AU2001262257A1/en
Application granted granted Critical
Publication of AU2001262257B2 publication Critical patent/AU2001262257B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001262257A 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists Ceased AU2001262257B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0010955.3 2000-05-05
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds
PCT/EP2001/005008 WO2001085727A1 (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

Publications (2)

Publication Number Publication Date
AU2001262257A1 AU2001262257A1 (en) 2002-02-07
AU2001262257B2 true AU2001262257B2 (en) 2004-11-04

Family

ID=9891092

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001262257A Ceased AU2001262257B2 (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
AU6225701A Pending AU6225701A (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptoragonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6225701A Pending AU6225701A (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptoragonists

Country Status (29)

Country Link
US (1) US6780861B2 (enExample)
EP (1) EP1282620B1 (enExample)
JP (1) JP4898062B2 (enExample)
KR (1) KR20020093974A (enExample)
CN (1) CN1167703C (enExample)
AR (1) AR028073A1 (enExample)
AT (1) ATE263167T1 (enExample)
AU (2) AU2001262257B2 (enExample)
BR (1) BR0110521A (enExample)
CA (1) CA2407972C (enExample)
CZ (1) CZ20023622A3 (enExample)
DE (1) DE60102581T2 (enExample)
DK (1) DK1282620T3 (enExample)
ES (1) ES2218418T3 (enExample)
GB (1) GB0010955D0 (enExample)
HK (1) HK1054223B (enExample)
HU (1) HUP0301866A2 (enExample)
IL (1) IL152417A0 (enExample)
MX (1) MXPA02010892A (enExample)
NO (1) NO20025280L (enExample)
NZ (1) NZ522226A (enExample)
PE (1) PE20020221A1 (enExample)
PL (1) PL357435A1 (enExample)
PT (1) PT1282620E (enExample)
RU (1) RU2002131886A (enExample)
SK (1) SK15612002A3 (enExample)
TR (1) TR200401007T4 (enExample)
WO (1) WO2001085727A1 (enExample)
ZA (1) ZA200208969B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005522456A (ja) * 2002-02-15 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
US6894042B2 (en) 2002-02-19 2005-05-17 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EE05516B1 (et) 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
SI1949901T1 (sl) 2002-12-06 2014-06-30 The Feinstein Institute For Medical Research Postopek ugotavljanja holinergičnega agonista selektivnega za nikotinski receptor alfa 7
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
JP2006521345A (ja) * 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
SG149830A1 (en) * 2003-12-22 2009-02-27 Memory Pharm Corp Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
ATE437880T1 (de) 2004-02-04 2009-08-15 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
SG165199A1 (en) 2004-03-25 2010-10-28 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
ATE487716T1 (de) * 2004-04-22 2010-11-15 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
RU2386633C2 (ru) * 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
PL1828179T3 (pl) * 2004-12-22 2010-08-31 Memory Pharm Corp Ligandy dla receptorów nikotynowych alfa-7 przeciwko chorobom związanym z OUN
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2355822B1 (en) 2008-11-19 2012-10-10 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
EP2456438A2 (en) * 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
WO2011119310A1 (en) * 2010-03-26 2011-09-29 Corning Incorporated Low nonlinearity long haul optical transmission system
RS54742B1 (sr) 2010-05-17 2016-10-31 Forum Pharmaceuticals Inc Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata
BR112013001939A2 (pt) 2010-07-26 2017-07-11 Envivo Pharmaceuticals Inc tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase
BR112013018726A2 (pt) * 2011-01-27 2016-10-25 Novartis Ag uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina
EP2685977A1 (en) * 2011-03-18 2014-01-22 Novartis AG COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
BR112013025682A2 (pt) * 2011-04-29 2017-01-03 Chiesi Farm Spa Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
JP6162705B2 (ja) 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CA2894384C (en) 2012-12-11 2018-03-06 Novartis Ag Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
CN105246485B (zh) * 2013-01-15 2019-03-15 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂的应用
ES2883232T3 (es) 2013-01-15 2021-12-07 Novartis Ag Uso de agonistas del receptor nicotínico de acetilcolina alfa 7
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
ES2701083T3 (es) 2013-01-15 2019-02-20 Novartis Ag Uso de agonistas del receptor nicotínico alfa 7 para el tratamiento de la narcolepsia
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US12083115B2 (en) 2020-02-03 2024-09-10 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1996008468A1 (en) 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EP0912563B1 (en) * 1996-06-05 2004-02-18 Lindner, Wolfgang, Prof. Dr. Cinchonan based chiral selectors for separation of stereoisomers
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
TWI282794B (en) * 1999-09-28 2007-06-21 Eisai R&D Man Co Ltd Quinuclidine compounds and drugs containing the same as the active ingredient
JP2004506735A (ja) * 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser

Also Published As

Publication number Publication date
PE20020221A1 (es) 2002-04-23
MXPA02010892A (es) 2003-03-27
US20030166654A1 (en) 2003-09-04
DE60102581T2 (de) 2005-02-03
BR0110521A (pt) 2003-04-08
ZA200208969B (en) 2003-10-07
GB0010955D0 (en) 2000-06-28
HK1054223A1 (en) 2003-11-21
HUP0301866A2 (hu) 2003-09-29
CA2407972C (en) 2010-03-09
PT1282620E (pt) 2004-07-30
JP4898062B2 (ja) 2012-03-14
CN1427840A (zh) 2003-07-02
EP1282620A1 (en) 2003-02-12
IL152417A0 (en) 2003-05-29
SK15612002A3 (sk) 2003-04-01
NZ522226A (en) 2004-08-27
JP2003532731A (ja) 2003-11-05
HK1054223B (en) 2005-03-04
DE60102581D1 (de) 2004-05-06
CA2407972A1 (en) 2001-11-15
ES2218418T3 (es) 2004-11-16
DK1282620T3 (da) 2004-07-19
ATE263167T1 (de) 2004-04-15
US6780861B2 (en) 2004-08-24
NO20025280D0 (no) 2002-11-04
AU6225701A (en) 2001-11-20
RU2002131886A (ru) 2004-04-10
EP1282620B1 (en) 2004-03-31
AR028073A1 (es) 2003-04-23
PL357435A1 (en) 2004-07-26
WO2001085727A1 (en) 2001-11-15
CN1167703C (zh) 2004-09-22
TR200401007T4 (tr) 2004-07-21
NO20025280L (no) 2002-11-04
CZ20023622A3 (cs) 2003-02-12
KR20020093974A (ko) 2002-12-16

Similar Documents

Publication Publication Date Title
AU2001262257B2 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
AU2001262257A1 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
CN1325501C (zh) 杂环化合物
JP5124714B2 (ja) アザビシクロアルキルエーテルおよびそのα７−ＮＡＣＨＲアゴニストとしての使用
EP1539764B1 (en) Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
NZ331145A (en) Azabicyclic esters of carbamic acids useful in treating disorders involving reduced cholinergic function
CA2493920A1 (en) Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
RS20060314A (sr) Derivati n-heterociklilmetilbenzamida, postupak za njihovo dobijanje i njihova upotreba kao leka
CN1659170A (zh) 噻吩基化合物
US5258392A (en) 3-quinuclidine derivatives
TW215090B (enExample)
JP3038018B2 (ja) 新規ｎ―アミノアルキル―２―アントラセンカルボキサミド；新規ドーパミン受容体サブタイプ特異的リガンド
US7683075B2 (en) Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
ES2352231T3 (es) Compuestos furilo.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired